US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
pharma · Hormone Receptor Positive Breast Carcinoma · ER+, HER2- Advanced Breast Cancer · OLMA
Olema Pharmaceuticals
Olema Pharmaceuticals drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Chennai, IN HQ
2 Employees
Public company Type
OLMA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Chennai, IN
- Employees
- 2
- Programs
- 7
- Drugs
- 17
- Patents
- 8
Olema Pharmaceuticals pipeline
Portfolio lens on 17 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Olema Pharmaceuticals drug portfolio — 17 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved.
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
US regulatory status: approved. Molecular target: Lanosterol 14-alpha demethylase.
- Target
- Lanosterol 14-alpha demethylase
- Mechanism
- Cytochrome P450 51 inhibitor
-
fulvestrant
Antineoplastic and immunomodulating agents (L02)US regulatory status: approved. Molecular target: Estrogen receptor.
- Target
- Estrogen receptor
- Mechanism
- Estrogen receptor antagonist
-
US regulatory status: approved. Mechanism: Gonadotropin-releasing hormone receptor agonist.
- Mechanism
- Gonadotropin-releasing hormone receptor agonist
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Aromatase.
- Target
- Aromatase
- Mechanism
- Cytochrome P450 19A1 inhibitor
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
ribociclib
Antineoplastic and immunomodulating agents (L01)US regulatory status: approved. Molecular target: Cyclin-dependent kinase 4.
- Target
- Cyclin-dependent kinase 4
- Mechanism
- Cyclin-dependent kinase 6 inhibitor
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.
-
Development asset linked to Olema Pharmaceuticals in public FDA and regional records.